Embecta Corp.

    Jurisdiction
    United States
    ISIN
    US29082K1051 (EMBC)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    Fair value (Benjamin Graham formula)
    €51.13 340.8% undervalued
    Financial strength (Piotroski F-Value)
    7 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €945.95M
    Gross margin
    62.8%
    EBIT
    €181.72M
    EBIT margin
    19.2%
    Net income
    €71.13M
    Net margin
    7.5%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €930.34M -1.7% €142.16M +99.9%
    €933.21M +0.3% €149.45M +5.1%
    €936.42M +0.3% €156.72M +4.9%

    Dividends

    Last dividend amount
    $0.15
    Ex date
    Payment date
    Dividend payout ratio
    42.1%

    Earnings Calls

    Latest earnings call: August 8, 2025

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 46K $592.21K -22K Sell

    Add to watchlist

    Notifications